• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Dec 1993; 92(6): 2577–2586.
PMCID: PMC288453

The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates.


This study examined the effect of 2 yr of treatment with the aminobisphosphonate alendronate (ALN) (0.05 or 0.25 mg/kg i.v. ALN every 2 wk) on estrogen deficiency bone loss and bone strength changes in ovariectomized (OVX) baboons (n = 7 per group) and the ALN mode of action at the tissue level. Biochemical markers of bone turnover increased in OVX animals and were maintained by ALN treatment at non-OVX levels (low dose) or below (high dose). 2 yr of treatment produced no cumulative effects on bone turnover markers. Histomorphometry showed a marked increase in cancellous bone remodeling in OVX animals. Activation frequency increased from 0.48 to 0.86 per yr (L5 vertebra), and the osteoid surfaces from 9 to 13.5% (P < 0.05). No changes were observed in eroded and osteoclast surfaces. ALN treatment decreased activation frequency and indices of bone formation to control levels (low dose) or below (high dose), did not change indices of mineralization, and increased bone mineral density (BMD) in the lumbar vertebrae (L2-L4) by 15% at 0.25 mg/kg (P < 0.05), relative to vehicle-treated animals. The mean strength of cancellous bone (L4) increased by 44% (low ALN dose) and 100% (high dose), compared with vehicle. The strength of individual bones correlated with the square of the L2-L4 BMD (r = 0.91, P < 0.0034). In conclusion, ALN treatment reversed the effects of ovariectomy on cancellous bone turnover and increased bone mass and bone strength in baboons.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.8M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Nordin BE, Chatterton BE, Walker CJ, Wishart J. The relation of forearm mineral density to peripheral fractures in postmenopausal women. Med J Aust. 1987 Mar 16;146(6):300–304. [PubMed]
  • Wasnich RD, Ross PD, Davis JW, Vogel JM. A comparison of single and multi-site BMC measurements for assessment of spine fracture probability. J Nucl Med. 1989 Jul;30(7):1166–1171. [PubMed]
  • Hui SL, Slemenda CW, Johnston CC., Jr Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med. 1989 Sep 1;111(5):355–361. [PubMed]
  • Cummings SR, Black DM, Nevitt MC, Browner WS, Cauley JA, Genant HK, Mascioli SR, Scott JC, Seeley DG, Steiger P, et al. Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA. 1990 Feb 2;263(5):665–668. [PubMed]
  • Cleghorn DB, Polley KJ, Bellon MJ, Chatterton J, Baghurst PA, Nordin BE. Fracture rates as a function of forearm mineral density in normal postmenopausal women: retrospective and prospective data. Calcif Tissue Int. 1991 Sep;49(3):161–163. [PubMed]
  • Chevalley T, Rizzoli R, Nydegger V, Slosman D, Tkatch L, Rapin CH, Vasey H, Bonjour JP. Preferential low bone mineral density of the femoral neck in patients with a recent fracture of the proximal femur. Osteoporos Int. 1991 Jun;1(3):147–154. [PubMed]
  • Gärdsell P, Johnell O, Nilsson BE. The predictive value of bone loss for fragility fractures in women: a longitudinal study over 15 years. Calcif Tissue Int. 1991 Aug;49(2):90–94. [PubMed]
  • Duboeuf F, Braillon P, Chapuy MC, Haond P, Hardouin C, Meary MF, Delmas PD, Meunier PJ. Bone mineral density of the hip measured with dual-energy X-ray absorptiometry in normal elderly women and in patients with hip fracture. Osteoporos Int. 1991 Sep;1(4):242–249. [PubMed]
  • Reginster JY, Lecart MP, Deroisy R, Sarlet N, Denis D, Ethgen D, Collette J, Franchimont P. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989 Dec 23;2(8678-8679):1469–1471. [PubMed]
  • Valkema R, Vismans FJ, Papapoulos SE, Pauwels EK, Bijvoet OL. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner. 1989 Jan;5(2):183–192. [PubMed]
  • Lindsay R. Prevention and treatment of osteoporosis with ovarian hormones. Ann Chir Gynaecol. 1988;77(5-6):219–223. [PubMed]
  • Reeve J. Bone turnover and trabecular plate survival after artificial menopause. Br Med J (Clin Res Ed) 1987 Sep 26;295(6601):757–760. [PMC free article] [PubMed]
  • Delmas PD, Schlemmer A, Gineyts E, Riis B, Christiansen C. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Miner Res. 1991 Jun;6(6):639–644. [PubMed]
  • Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD. Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J Clin Endocrinol Metab. 1991 Feb;72(2):367–373. [PubMed]
  • Stepán JJ, Pospíchal J, Presl J, Pacovský V. Bone loss and biochemical indices of bone remodeling in surgically induced postmenopausal women. Bone. 1987;8(5):279–284. [PubMed]
  • Frost HM. The pathomechanics of osteoporoses. Clin Orthop Relat Res. 1985 Nov;(200):198–225. [PubMed]
  • Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 1986 Jun;38(6):342–349. [PubMed]
  • Thompson DD, Seedor JG, Weinreb M, Rosini S, Rodan GA. Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats. J Bone Miner Res. 1990 Mar;5(3):279–286. [PubMed]
  • Weinreb M, Rodan GA, Thompson DD. Osteopenia in the immobilized rat hind limb is associated with increased bone resorption and decreased bone formation. Bone. 1989;10(3):187–194. [PubMed]
  • Seedor JG, Quartuccio HA, Thompson DD. The bisphosphonate alendronate (MK-217) inhibits bone loss due to ovariectomy in rats. J Bone Miner Res. 1991 Apr;6(4):339–346. [PubMed]
  • O'Doherty DP, Bickerstaff DR, McCloskey EV, Hamdy NA, Beneton MN, Harris S, Mian M, Kanis JA. Treatment of Paget's disease of bone with aminohydroxybutylidene bisphosphonate. J Bone Miner Res. 1990 May;5(5):483–491. [PubMed]
  • Passeri M, Baroni MC, Pedrazzoni M, Pioli G, Barbagallo M, Costi D, Biondi M, Girasole G, Arlunno B, Palummeri E. Intermittent treatment with intravenous 4-amino-1-hydroxybutylidene-1,1-bisphosphonate (AHBuBP) in the therapy of postmenopausal osteoporosis. Bone Miner. 1991 Dec;15(3):237–247. [PubMed]
  • Turner RT, Vandersteenhoven JJ, Bell NH. The effects of ovariectomy and 17 beta-estradiol on cortical bone histomorphometry in growing rats. J Bone Miner Res. 1987 Apr;2(2):115–122. [PubMed]
  • Wronski TJ, Cintrón M, Dann LM. Temporal relationship between bone loss and increased bone turnover in ovariectomized rats. Calcif Tissue Int. 1988 Sep;43(3):179–183. [PubMed]
  • Boyce RW, Franks AF, Jankowsky ML, Orcutt CM, Piacquadio AM, White JM, Bevan JA. Sequential histomorphometric changes in cancellous bone from ovariohysterectomized dogs. J Bone Miner Res. 1990 Sep;5(9):947–953. [PubMed]
  • Mazess B, Vetter J, Weaver DS. Bone changes in oophorectomized monkeys: CT findings. J Comput Assist Tomogr. 1987 Mar-Apr;11(2):302–305. [PubMed]
  • Longcope C, Hoberg L, Steuterman S, Baran D. The effect of ovariectomy on spine bone mineral density in rhesus monkeys. Bone. 1989;10(5):341–344. [PubMed]
  • Jerome CP, Kimmel DB, McAlister JA, Weaver DS. Effects of ovariectomy on iliac trabecular bone in baboons (Papio anubis). Calcif Tissue Int. 1986 Sep;39(3):206–208. [PubMed]
  • Thompson DD, Seedor JG, Quartuccio H, Solomon H, Fioravanti C, Davidson J, Klein H, Jackson R, Clair J, Frankenfield D, et al. The bisphosphonate, alendronate, prevents bone loss in ovariectomized baboons. J Bone Miner Res. 1992 Aug;7(8):951–960. [PubMed]
  • Beardsworth LJ, Eyre DR, Dickson IR. Changes with age in the urinary excretion of lysyl- and hydroxylysylpyridinoline, two new markers of bone collagen turnover. J Bone Miner Res. 1990 Jul;5(7):671–676. [PubMed]
  • Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner. 1990 Jan;8(1):87–96. [PubMed]
  • Parfitt AM, Mathews CH, Villanueva AR, Kleerekoper M, Frame B, Rao DS. Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis. Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest. 1983 Oct;72(4):1396–1409. [PMC free article] [PubMed]
  • Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR. Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res. 1987 Dec;2(6):595–610. [PubMed]
  • Carter DR, Hayes WC. The compressive behavior of bone as a two-phase porous structure. J Bone Joint Surg Am. 1977 Oct;59(7):954–962. [PubMed]
  • Stepán JJ, Pospíchal J, Schreiber V, Kanka J, Mensík J, Presl J, Pacovský V. The application of plasma tartrate-resistant acid phosphatase to assess changes in bone resorption in response to artificial menopause and its treatment with estrogen or norethisterone. Calcif Tissue Int. 1989 Nov;45(5):273–280. [PubMed]
  • Kelly PJ, Pocock NA, Sambrook PN, Eisman JA. Age and menopause-related changes in indices of bone turnover. J Clin Endocrinol Metab. 1989 Dec;69(6):1160–1165. [PubMed]
  • Smith ML, Fogelman I, Hart DM, Scott E, Bevan J, Leggate I. Effect of etidronate disodium on bone turnover following surgical menopause. Calcif Tissue Int. 1989 Feb;44(2):74–79. [PubMed]
  • Genant HK, Cann CE, Ettinger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med. 1982 Nov;97(5):699–705. [PubMed]
  • Hreshchyshyn MM, Hopkins A, Zylstra S, Anbar M. Effects of natural menopause, hysterectomy, and oophorectomy on lumbar spine and femoral neck bone densities. Obstet Gynecol. 1988 Oct;72(4):631–638. [PubMed]
  • Lindsay R, Hart DM, Forrest C, Baird C. Prevention of spinal osteoporosis in oophorectomised women. Lancet. 1980 Nov 29;2(8205):1151–1154. [PubMed]
  • Civitelli R, Agnusdei D, Nardi P, Zacchei F, Avioli LV, Gennari C. Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D-1 alpha-hydroxylase reserve in postmenopausal osteoporosis. Calcif Tissue Int. 1988 Feb;42(2):77–86. [PubMed]
  • Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Melsen F. A randomized study on the effects of estrogen/gestagen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone. 1989;10(5):313–320. [PubMed]
  • Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, 3rd, Yanover MJ, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990 Jul 12;323(2):73–79. [PubMed]
  • Mazzuoli GF, Tabolli S, Bigi F, Valtorta C, Minisola S, Diacinti D, Scarnecchia L, Bianchi G, Piolini M, Dell'Acqua S. Effects of salmon calcitonin on the bone loss induced by ovariectomy. Calcif Tissue Int. 1990 Oct;47(4):209–214. [PubMed]
  • Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 1990 Jan;5(1):31–40. [PubMed]
  • Zysset E, Ammann P, Jenzer A, Gertz BJ, Portmann L, Rizzoli R, Jaquet-Müller F, Pryor-Tillotson S, Bonjour JP, Burckhardt P. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy. Bone Miner. 1992 Sep;18(3):237–249. [PubMed]
  • Delmas PD. Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease. Endocrinol Metab Clin North Am. 1990 Mar;19(1):1–18. [PubMed]
  • Ohta H, Makita K, Suda Y, Ikeda T, Masuzawa T, Nozawa S. Influence of oophorectomy on serum levels of sex steroids and bone metabolism and assessment of bone mineral density in lumbar trabecular bone by QCT-C value. J Bone Miner Res. 1992 Jun;7(6):659–665. [PubMed]
  • Moore RJ, Durbridge TC, Woods AE, Vernon-Roberts B. Variation in histomorphometric estimates across different sites of the iliac crest. J Clin Pathol. 1989 Aug;42(8):814–816. [PMC free article] [PubMed]
  • Grynpas MD, Acito A, Dimitriu M, Mertz BP, Very JM. Changes in bone mineralization, architecture and mechanical properties due to long-term (1 year) administration of pamidronate (APD) to adult dogs. Osteoporos Int. 1992 Mar;2(2):74–81. [PubMed]
  • Mellish RW, Ferguson-Pell MW, Cochran GV, Lindsay R, Dempster DW. A new manual method for assessing two-dimensional cancellous bone structure: comparison between iliac crest and lumbar vertebra. J Bone Miner Res. 1991 Jul;6(7):689–696. [PubMed]
  • Storm T, Steiniche T, Thamsborg G, Melsen F. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res. 1993 Feb;8(2):199–208. [PubMed]
  • Jensen KS, Mosekilde L, Mosekilde L. A model of vertebral trabecular bone architecture and its mechanical properties. Bone. 1990;11(6):417–423. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...